Resources
48 Results (showing 21 - 30)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 12/22/2021 (updated 3/26/2024)
This Rural Health Care Chartbook is part of a family of documents and tools that support the National Healthcare Quality and Disparities Report (NHQDR). The NHQDR includes annual reports to Congress mandated in the Healthcare Research and Quality Act of 1999 (P.L. 106- 129). These reports provide a comprehensive overview of the quality of healthcare received by the general U.S. population and disparities in care experienced by different racial, ethnic, and socioeconomic groups. The reports assess the performance of our health system and identify areas of strength and weakness in the healthcare system along four main axes: access to healthcare, quality of healthcare, disparities in healthcare, and Agency for Healthcare Research and Quality (AHRQ) priority areas. The reports are based on more than 250 measures of quality and disparities covering a broad array of healthcare services and settings. Data are generally available through 2017-2018. The reports are produced with the help of an Interagency Work Group led by AHRQ and submitted on behalf of the Secretary of Health and Human Services (HHS).
Posted 11/17/2021 (updated 4/3/2024)
Opioid use disorder (OUD) is a public health crisis affecting women, men, children, and society.1 Women with OUD have unique care needs and require a broad range of medical, behavioral health, and social services to meet these needs. Care coordination is important to manage the array of services that might be delivered to women in different settings. Without care coordination, women with OUD might struggle to access the services they need to get treatment and maintain recovery.
Posted 9/15/2021 (updated 4/2/2024)
Background: Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U.S. The purpose of this study is to explore the social and relational factors that shape the current opioid overdose epidemic.
Posted 9/15/2021 (updated 4/2/2024)
Background: Rates of fatal overdose (OD) from synthetic opioids rose nearly 60 % from 2016 to 2018. 911 Good Samaritan Laws (GSLs) are an evidenced-based strategy for preventing OD fatality. This study describes patrol officers’ knowledge of their state’s GSL, experience with OD response, and their perspectives on strategies to prevent and respond to opioid OD.
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 8/4/2021 (updated 4/2/2024)
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.